Altimmune to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024

Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its first quarter 2024 financial results on Thursday, May 9, 2024 and will provide a business update.

Altimmune management will host a conference call at 8:30 am E.T. on May 9 to discuss financial results and provide a business update. The conference call will be webcast live on Altimmune’s Investor Relations website at https://ir.altimmune.com/investors.

Participants who would like to join the call may register here to receive the dial-in numbers and unique PIN to access the call. Shortly after the call, a replay will be available on the Investor Relations website for up to three months.

About Altimmune

Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity and MASH. For more information, please visit www.altimmune.com.

Follow @Altimmune, Inc. on LinkedInFollow @AltimmuneInc on Twitter

Company Contact:Richard Eisenstadt                                                        Chief Financial Officer                                                 Phone: [phone]                                                        [e-mail]

Investor Contact:Lee RothBurns McClellanPhone: [e-mail] Julia WeilmanBurns McClellanPhone: [e-mail]

Media Contact:Danielle CanteyInizio Evoke CommsPhone: [e-mail]